Tag: biosimilar

biosimilar

Latest News

Celltrion signs $316 million biosimilars supply deal

Celltrion signed a 423.6 billion won ($316 million) supply deal with Celltrion Healthcare, its distributor, the biopharmaceutical company said Monday.

2023.9.25

Samsung Bioepis headquarters in Songdo, Incheon [SAMSUNG BIOEPIS]

Samsung, Sandoz sign deal to commercialize biosimilar SB17

Samsung Bioepis signed an agreement with Switzerland’s Sandoz for the sales of its Stelara biosimilar drug in the North American and European regions.

2023.9.11

Most popular

Celltrion invests $94.5 million to build drug production plant

Celltrion is investing 126 billion won ($94.5 million) by 2026 to build a production facility for drug products in Songdo, Incheon, the biopharmaceutical company said Tuesday.

2023.9.5

Vegzelma, a Celltrion biosimilar of the anticancer drug Avastin [CELLTRION]

Vegzelma, Celltrion's Avastin biosimilar, approved for sale in Australia

Celltrion's biosimilar of the anti-cancer drug Avastin, marketed as Vegzelma, was approved for sale in Australia, the Incheon-based biopharmaceutical company said Wednesday.

2023.9.4

Celltrion headquarters in Incheon [CELLTRION]

Celltrion reaches patent agreement for Stelara biosimilar CT-P43

Celltrion reached a patent agreement for its copycat drug of Stelara, a blockbuster psoriasis treatment by Janssen Pharmaceuticals, with Janssen’s parent company Johnson & Johnson (J&J).

2023.8.25

Samsung Bioepis ponders acquiring unit from U.S. partner Biogen

Samsung Bioepis is mulling the acquisition of a biosimilar business unit from its long-standing overseas partner Biogen, according to local media reports citing financial industry sources.

2023.8.2

Samsung Bioepis' Hadlima, its Humira biosimilar [SAMSUNG BIOEPIS]

Samsung Bioepis completes interchangeability study for Humira biosimilar

Samsung Bioepis’ Hadlima, a biosimilar of blockbuster autoimmune diseases drug Humira, met primary endpoints in the interchangeability test, the Incheon-based pharmaceutical company said Wednesday.

2023.8.2

Celltrion headquarters in Songdo, Incheon [CELLTRION]

Celltrion looks to expand biosimilar line by 2025

Celltrion hopes to submit drug approval applications for up to five new biosimilars by the end of this year, the Incheon-based biopharmaceutical company said Tuesday.

2023.6.13

Celltrion beats market consensus with net $126 million in first quarter

Celltrion reported a consensus-beating net profit of 167.1 billion won ($126.4 million) in the first quarter on strong sales of biosimilar products.

2023.5.8

A Celltrion researcher conducts a test of its biosimilar product at the company's lab in Songdo, Incheon. [CELLTRION]

[ANALYSIS] Korean Humira biosimilars set for huge 2023

With Humira, the world’s top-selling drug for over a decade, losing its monopoly, Korean biosimilar makers are gearing up to tap into the approximately $20-billion market.

2023.2.18